Claims for Patent: 10,864,209

Summary for Patent: 10,864,209

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	16/825,228
Patent Claims:	1. A method of treating treatment resistant depression, comprising orally co-administering: a daily dose of bupropion that is about 150 mg to about 250 mg and a daily dose of dextromethorphan that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion is bupropion hydrochloride, or the free base or another salt form of bupropion and the dextromethorphan is dextromethorphan hydrobromide, or the free base or another salt form of dextromethorphan; wherein the bupropion and the dextromethorphan are the only therapeutically active compounds to be co-administered; wherein the dextromethorphan is formulated for immediate release and the bupropion is formulated for sustained release; and wherein orally co-administering the bupropion and the dextromethorphan is more effective in treating treatment resistant depression than orally administering the same amount of the bupropion alone for the same number of consecutive days. 2. The method of claim 1, wherein orally co-administering the bupropion and the dextromethorphan is more effective in treating treatment resistant depression than orally administering the same amount of the dextromethorphan alone for the same number of consecutive days. 3. The method of claim 1, wherein the daily dose of the bupropion is orally administered once daily and the daily dose of the dextromethorphan is orally administered once daily. 4. The method of claim 1, wherein one half of the daily dose of the bupropion is orally administered twice daily and one half of the daily dose of the dextromethorphan is orally administered twice daily. 5. The method of claim 1, wherein the bupropion and the dextromethorphan are orally administered for at least 14 consecutive days. 6. The method of claim 1, wherein the bupropion and the dextromethorphan are orally administered for at least 30 consecutive days. 7. The method of claim 1, wherein the bupropion is in a solid dosage form. 8. The method of claim 1, wherein the dextromethorphan is in a solid dosage form. 9. The method of claim 1, wherein the human being has a C.sub.avg of bupropion that is at least about 10 ng/mL after orally co-administering the bupropion and the dextromethorphan. 10. The method of claim 1, wherein the human being has a C.sub.max of bupropion that is at least about 90 ng/mL after orally co-administering the bupropion and the dextromethorphan. 11. The method of claim 1, wherein a daily dose of bupropion hydrochloride is about 210 mg and a daily dose of dextromethorphan hydrobromide is about 60 mg to about 100 mg. 12. The method of claim 11, wherein orally co-administering the bupropion and the dextromethorphan is more effective in treating treatment resistant depression than orally administering 105 mg of bupropion hydrochloride twice a day for the same number of consecutive days.